Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

The addition of pembrolizumab to chemotherapy for metastatic lung cancer without EGFR or ALK mutations resulted in better progression-free and overall survival than chemotherapy alone. Immune-related adverse effects were more common with the combination.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2018-05, Vol.378 (22), p.2078-2092
Hauptverfasser:	Gandhi, Leena, Rodríguez-Abreu, Delvys, Gadgeel, Shirish, Esteban, Emilio, Felip, Enriqueta, De Angelis, Flávia, Domine, Manuel, Clingan, Philip, Hochmair, Maximilian J, Powell, Steven F, Cheng, Susanna Y.-S, Bischoff, Helge G, Peled, Nir, Grossi, Francesco, Jennens, Ross R, Reck, Martin, Hui, Rina, Garon, Edward B, Boyer, Michael, Rubio-Viqueira, Belén, Novello, Silvia, Kurata, Takayasu, Gray, Jhanelle E, Vida, John, Wei, Ziwen, Yang, Jing, Raftopoulos, Harry, Pietanza, M. Catherine, Garassino, Marina C
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Agents, Immunological - adverse effects Antineoplastic Agents, Immunological - therapeutic use Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Apoptosis Cancer therapies Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - mortality Carcinoma, Non-Small-Cell Lung - secondary Chemotherapy Cytotoxicity Death Disease-Free Survival Double-Blind Method Epidermal growth factor receptors Female Follow-Up Studies Hospitals Humans Immunotherapy Kaplan-Meier Estimate Laboratories Lung cancer Lung Neoplasms - drug therapy Lung Neoplasms - genetics Lung Neoplasms - mortality Lung Neoplasms - pathology Male Metastases Metastasis Middle Aged Monoclonal antibodies Mutation Non-small cell lung carcinoma Patients PD-L1 protein Pembrolizumab Platinum Response rates Targeted cancer therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The addition of pembrolizumab to chemotherapy for metastatic lung cancer without EGFR or ALK mutations resulted in better progression-free and overall survival than chemotherapy alone. Immune-related adverse effects were more common with the combination.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa1801005